BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced the presentation of preclinical data from the Company’s lead asset, Plinabulin, at the American Association for Cancer Research (AACR) Annual Meeting, being held on April 14-18, 2018, at McCormick Place in Chicago. The preclinical data will be presented in a poster titled, “Plinabulin ameliorates chemotherapy-induced neutropenia: Mechanistic insights,” from 1:00 to 5:00 p.m. CDT at the McCormick Place North / South Exhibit Hall (Poster Session 37, Abstract No. 4805 / 4). The data demonstrate Plinabulin’s novel mechanism in preserving neutrophil (a type of white blood cell) amount in bone marrow after docetaxel treatment, a mechanism that is differentiated from that of G-CSF, which is the current standard of care, in the prevention of chemotherapy-induced neutropenia (CIN).